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Abstract
While much research has been directed to harnessing the antimicrobial properties of exogenous
NO, the possibility of bacteria developing resistance to such therapy has not been thoroughly
studied. Herein, we evaluate potential NO resistance using spontaneous and serial passage
mutagenesis assays. Specifically, Staphylococcus aureus, Methicillin-resistant S. aureus (MRSA),
Staphylococcus epidermidis, Escherichia coli, and Pseudomonas aeruginosa were systematically
exposed to NO-releasing 75mol% MPTMS-TEOS nitrosothiol particles at or below minimum
inhibitory concentration (MIC) levels. In the spontaneous mutagenesis assay, bacteria that
survived exposure to lethal concentrations of NO showed no increase in MIC. Similarly, no
increase in MIC was observed in the serial passage mutagenesis assay after exposure of these
species to sub-inhibitory concentrations of NO through 20 d.
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1.1 Introduction
Nitric oxide (NO) is an endogenous diatomic free radical implicated in several physiological
processes including vasodilation, immune response, neurotransmission, and wound healing.
[1] During infection, NO is released by macrophages and other immune cells at >1 μM
concentrations where it serves as a broad spectrum biocidal agent.[1,2,3,4,5,6] Nitric oxide
induces both nitrosative and oxidative stress that results in numerous toxic effects on
bacteria, including direct modification of membrane proteins, lipid peroxidation, and DNA
cleavage.[1,6,7,8] As such, the exogenous application of NO as a therapy has been the
subject of intense interest during the past decade.[9,10,11,12,13,14,15]
© 2012 Elsevier Inc. All rights reserved
cCorresponding author, University of North Carolina at Chapel Hill, Department of Chemistry, Caudill Hall, CB #3290, Chapel Hill,
NC 27599, schoenfisch@unc.edu, Tel: +1 919 843 8714, Fax: +1 919 962 2388,.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Nitric Oxide. Author manuscript; available in PMC 2013 March 31.
Published in final edited form as:













Controlled NO storage and delivery using chemical NO donors has led to several
pharmacological applications.[16] Example antimicrobial NO delivery vehicles include low
molecular weight compounds (e.g., sodium nitroprusside, N-diazeniumdiolated proline, and
S-nitroso-N-acetylpenicillamine),[17,18,19] macromolecular vehicles,[14,20,21,22,23,24]
and polymeric coatings.[10,25,26,27,28,29,30,31,32,33] We have previously reported the
bactericidal activity of NO-releasing silica nanoparticles and sol-gel-derived xerogel films
against Pseudomonas aeruginosa at concentrations of minimal toxicity to mammalian cells.
[11,13]
It is known that bacteria possess mechanisms for reducing the pharmacological effects of
drugs such as antibiotics by directly removing the drug (i.e., efflux pumps), reduced drug
diffusion via porin loss or modification, overproduction or alterations of drug target sites, or
enzymatic drug degradation.[34,35,36,37,38,39,40] For example, Charrel et al. reported that
some β-lactam antibiotic-resistant Enterobacter aerogenes were porin deficient, resulting in
a high MIC for β-lactam even in the absence of increased β-lactamase production.[41]
Recent research also indicates that select bacteria are capable of up-regulating NO
scavengers[42,43,44,45,46] and/or altering respiration in response to endogenous NO.[47]
An example is NO detoxification by flavohemoglobin, a protein that is up-regulated in E.
coli in response to macrophage-produced NO.[45] Endogenous thiols such as mycothiol, a
glutathione analog produce by mycobacteria, have also been shown to reduce the toxicity of
NO and other oxygen species.[48,49] Enzymes including reductases and superoxide
dismutase have been implicated to serve similar functions.[45,50] With respect to cellular
respiration, Husain et al. reported arrested respiration in Salmonella with concomitant
accumulation of nicotinamide adenine dinucleotide (NADH), thereby increasing the ability
of the bacteria to resist oxidative stress.[47]
While the antimicrobial action of NO-releasing materials is established,
[11,12,13,29,51,52,53] knowledge about the bacterial resistance to exogenous
concentrations of NO remains scarce.[42,43,44,45,46,47,54] Miller et al. reported that S.
aureus was not capable of developing resistance to exogenous gaseous NO; however, NO
exposure was intermittent with discontinuous selective pressure against the NO-susceptible
bacteria.[15,55,56,57] Herein, we report a thorough bacterial resistance study using both
spontaneous mutation and serial passage mutagenesis assays with continuous exposure to
physiologically relevant concentrations of NO from NO-releasing silica nanoparticles.
Representative gram positive and gram negative bacteria were selected to provide
preliminary resistance information as a function of bacteria classification and structure.
1.2 Material and Methods
1.2.1 Strains, media, and chemical reagents
3-Mercaptopropyltrimethoxysilane (MPTMS) and tetraethoxysilane (TEOS) were purchased
from Gelest (Tullytown, PA). Bacteria were propagated at 37 °C in tryptic soy broth (TSB)
and agar (TSA, Becton, Dickinson, Franklin Lakes, NJ). Sodium chloride, potassium
chloride, sodium phosphate monobasic, methanol, ethanol, ammonium hydroxide, and
hydrochloric acid were obtained from Fisher Scientific (Pittsburgh, PA). Sodium phosphate
dibasic and sodium nitrite were obtained from Sigma Aldrich (St. Louis, MO). Escherichia
coli O157:H7 (35150), Pseudomonas aeruginosa (19143), methicillin-susceptible
Staphylococcus aureus (MSSA) (29213), methicillin-resistant Staphylococcus aureus
(MRSA) (33591), and Staphylococcus epidermidis (35983) were obtained from American
Type Culture Collection (ATCC, Manassas, VA). Distilled water was purified to 18.2
MΩ·cm with a Millipore Milli-Q Gradient A-10 water purification system (Bedford, MA).
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1.2.2 Synthesis of mercaptosilane-based silica particles
Nitrosothiol particles (75 mol% MPTMS/TEOS) were synthesized following a procedure
reported previously.[21] Briefly, 3-mercaptopropyltrimethoxysilane (MPTMS, 424 μL) and
tetraethoxysilane (TEOS, 169 μL) were mixed and added dropwise via a Kent Scientific
Genie Plus syringe pump at a flow rate of 0.5 mL min−1 through an 18.5 gauge needle to a
solution of ethanol (16.3 mL), water (1.4 mL), and ammonium hydroxide (11 mL). The
reaction was stirred for 2 h at room temperature and the particles collected by centrifugation
at 3645g (10 min), washed twice with 40 mL EtOH, recollected, and dried overnight at
ambient conditions.
1.2.3 Nitrosation of mercaptosilane-based silica particles
Thiols within the particles were nitrosated upon reaction with nitrous acid as follows.
Particles (~200 mg) were first added to 4 mL methanol (MeOH). While stirring, 2 mL of
hydrochloric acid (5 M) was added to the suspension. A 2 mL aqueous solution containing
sodium nitrite (2× molar excess to thiol) and DTPA (500 μM) was then added to the particle
suspension, and the mixture was stirred for 2 h in the dark on ice. Particles were collected by
centrifugation at 3645g (5 min), washed with 40 mL chilled 500 μM DTPA(aq), recollected,
washed with 40 mL chilled MeOH, recollected, and vacuum dried in the dark for 30 min.
Particles were stored at −20 °C in vacuo until used.
1.2.4 Nitric oxide release characterization
Real-time NO release from 75 mol% MPTMS/TEOS particles was measured at 1 s intervals
using a Sievers Chemiluminescence Nitric Oxide Analyzer (Boulder, CO). Particles were
added to 25 mL deoxygenated TSB (37 °C) containing 50 μL antifoaming agent B (Sigma-
Aldrich) to prevent frothing. Decomposition of the nitrosothiol to release NO was initiated
by the heat of the solution and trace amounts of free copper likely present in the TSB
solution. The solution was sparged with nitrogen (80 mL/min) with additional nitrogen was
supplied to the reaction flask to match the collection rate of the NOA (200 mL min−1). The
apparatus was covered with aluminum foil to prevent light-initiated nitrosothiol
decomposition.
1.2.5 Minimum inhibitory concentration assay
Bacterial cultures were grown from an overnight stock in TSB to 108 colony forming units
(cfu) mL−1 and diluted to 2 × 106 cfu ml−1. Bacteria were added to serial dilutions of
nitrosothiol particles in a 96-well plate resulting in a final concentration of 106 cfu mL−1
bacteria. After incubating by shaking for 24 h at 37 °C, MIC values were determined as the
lowest particle concentration not supporting bacterial growth (i.e., not turbid).
1.2.6 Spontaneous resistance assay
Bacterial cultures were grown from an overnight stock in TSB to ~109 cfu mL−1. A 1-mL
aliquot of the 109 cfu mL−1 culture was added to NO-releasing particles at 2–8× the MIC
measured for each bacterial species. Following a 24 h incubation at 37 °C in the dark with
agitation, 1 mL of each concentration was plated on TSA (200 μL on 5 separate plates) and
incubated overnight at 37 °C. Surviving colonies were propagated overnight at 37 °C in
TSB, reinoculated and grown to 108 cfu mL−1. The MICs for propagated strains were
determined using the above procedure and compared to the parent strain. Surviving colonies
on TSA that could not be propagated in TSB were passaged on TSA for three days and then
grown in TSB overnight at 37 °C. If overnight growth in TSA was successful, the MIC was
then evaluated and compared to the parent strain. Otherwise, formation and settling of a
bacterial precipitate did not allow an MIC assay to be performed.
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1.2.7 Serial passage assay
Bacterial cultures were grown from an overnight stock in TSB to 108 cfu mL−1 and diluted
to 2 × 106 cfu mL−1. The bacterial suspensions were then added to serial dilutions of
nitrosothiol particles in a 96-well plate resulting in wells containing 106 cfu mL−1 bacteria
and nitrosothiol particle concentrations of 2, 1, 0.5, 0.25, and 0.125× the MIC (n=3). After
incubating by shaking for 24 h at 37 °C, MIC values were recorded, and an aliquot from the
well containing the highest particle concentration that supported bacterial growth was
diluted to 2 × 106 cfu mL−1. The MIC assay was performed using this bacterial suspension.
The entire process was repeated for 20 exposure cycles.
1.3 Results and Discussion
The bacterial species used in these studies were selected because they are frequently found
in a clinical environment. While gaseous NO has proven useful for pulmonary treatment, it
is generally not a good candidate for an antimicrobial therapeutic. The short half-life (<10 s)
of NO in physiological milieu prevents its delivery to common infection sites such as an
indwelling medical device (i.e., catheter) or deep wound. As such, nanoparticles chemically
modified to store and release NO have been studied as candidate antimicrobials.[12,13,14]
We have previously described particles that release NO over extended periods (from
minutes to days), allowing more targeted NO delivery, thus ensuring more lethal
concentrations of NO. Indeed, Hetrick and coworkers reported excellent efficacy of NO-
releasing particles against both planktonic and biofilm-based bacteria.[12,13] To date, the
only studies that have examined bacterial resistance to exogenous NO have used NO gas
from cylinders.[15,55,56,57] Martinez and Baquero demonstrated that the development of
resistant bacteria depends on antibiotic exposure parameters (i.e., concentration and
kinetics).[58] Thus, we utilized chemically-stored NO release for these studies to more fully
evaluate resistance potential. In particular, nitrosothiol-based NO-releasing particles were
selected because their extended NO release capabilities (>24 h) facilitate continuous
selective pressure for resistant mutants whereas low molecular weight N-diazeniumdiolate
NO donors tend to release their NO payload more quickly, especially in aqueous media.
[13,21]
The NO release profile of 75 mol% MPTMS-TEOS particles (635 ± 63 nm diameter) in
TSB at 37 °C is shown in Figure 1. To mimic the conditions used during the bacteria assays,
NO release measurements were conducted in the absence of light such that NO production
was limited to thermal decomposition and not photolytic cleavage. Upon addition to the
assay media (2 mg mL−1 final particle concentration) (TSB,37 °C), a bolus of NO was
released at ~740 ppb mg−1 s−1. This level of NO decreased with time, ultimately dropping
to ~11 ppb mg−1 s−1 after 24 h. Over the course of the assay, a total of 0.90 μmol mg−1 was
released per mg of particles. Both the maximum instantaneous and the total NO released
from the particles in TSB were slightly lower than reported previously in PBS (1205 ppb
mg−1 s−1 and 1.17 μmol mg−1, respectively), which is likely due to reactions between NO
and proteins present in TSB.[21]
1.3.1 Minimum inhibitory concentration determinations
Minimum inhibitory concentrations were used to rapidly determine the efficacy of the NO
release and monitor for the emergence of resistance.[58,59,60,61] As shown in Table 1, the
MICs were used for both the spontaneous and serial passage mutagenesis assays. The MIC
of 75 mol% MPTMS/TEOS particles for each bacterial species was determined under
growth conditions (TSB, 37 °C) over 24 h. The measured MICs ranged from 3.13 to 6.25
mg mL−1 across all bacterial species (Table 1).Of note, the MICs for both methicillin-
susceptible and -resistant S. aureus were half that of S. epidermidis and the two Gram
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negative species, E. coli and P. aeruginosa. Representative Gram positive and Gram
negative bacteria, S. aureus and P. aeruginosa, were also exposed to control (non-
nitrosated) particles at concentrations equivalent to the MIC for nitrosated particles. No
inhibition was observed, indicating that NO, rather than the particles, are responsible for the
antimicrobial activity.
1.3.2 Spontaneous mutagenesis assay
Even after exposure to bactericidal doses of an antimicrobial, some microbes may survive
depending on the antimicrobial concentration, environmental conditions, and microbial
species.[58] In the case of antibiotics, some of the surviving microbes are the result of a
spontaneous mutation that confers greater resistance to future treatment.[58] Thus, the rate
of spontaneous mutations occurring at inhibitory NO concentrations was evaluated for each
bacterial species to address the possibility of NO-resistance. Nitric oxide-releasing particle
concentrations ranging from 2 to 8 times the MIC were utilized to provide adequate
selective pressure against NO-susceptible bacteria. Surviving colonies were isolated and
propagated in TSB, and the MIC assays were repeated to observe if the microbes were more
or less susceptible to NO treatment. Exposure of E. coli to NO-releasing particles at 2 times
the MIC resulted in 19 surviving colonies in 1 mL. Each colony was reinoculated in TSB,
and all resulted in a cloudy suspension after overnight incubation. An MIC assay was
performed individually on each colony and the susceptibility of all 19 colonies was
unchanged from the parent strain (6.25 mg mL−1). Nanoparticle exposure to MRSA at 7
times the MIC resulted in one surviving colony in 1 mL. Although the MIC of this survivor
was increased by 2 times to 6.25 mg mL−1, this increase is considered to be within the
experimental variation and is thus not significant. After exposure of P. aeruginosa to 2 times
the MIC, 7 surviving colonies were isolated and propagated successfully in TSB. The MIC
of all P. aeruginosa survivors was increased two fold to 12.5 mg mL−1, but again this
increase is within the experimental variation and not significant.
Some colonies that were able to survive NO treatment were not able to grow successfully in
TSB. These colonies were instead propagated three times on TSA to assess if the mutation
that limited growth in broth was stable. After exposure of S. epidermidis to 4 times the MIC,
two of the three surviving colonies could not be propagated further in TSB, even after three
successful passages on TSA. Regrowth of the bacterial precipitate was possible on TSA.
However, the inability of the S. epidermidis to grow to turbidity in fresh TSB prevented the
determination of the MIC. The spontaneous mutation that resulted in this NO tolerance
seemed to have prevented regrowth in nutrient broth. Others have observed similar behavior
where mutations conferring resistance to a therapeutic also result in a fitness cost to the
bacteria, sometimes preventing further propagation.[62,63] A third colony of S. epidermidis
was successfully regrown in TSB, but viability was not evident following NO exposure even
at 1/8 of the MIC. To assess the fitness of this colony, it was propagated three times in
succession on TSA and then inoculated in TSB. The solution again grew to a cloudy
suspension overnight. An MIC assay was successfully completed and found to be identical
to the parent strain (~6.25 mg mL−1). These results indicate that for one mutant, the growth
defect preventing propagation in TSB in the absence of NO was resolved, possibly due to a
second mutation that also abolished the observed increase in NO resistance. Methicillin-
susceptible S. aureus exposed to 8 times the MIC resulted in 12 surviving colonies on TSA.
Reinoculation of each colony in TSB produced a precipitate similar to that of the S.
epidermidis colonies described above. Similarly, the colony failed to successfully grow to a
cloudy suspension in TSB after regrowth on TSA three times in succession. Therefore, no
MIC assay was performed. However, propagation of the aggregated bacteria on TSA was
successful. A comparison of all parameters (initial and final MIC, survivors, and colonies
propagated in TSB) is shown in Table 1.
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1.3.3 Serial passage assay
Repeated exposure to sub-therapeutic concentrations of antibiotics often hastens the
development of antibiotic-resistant bacteria.[64,65] Genetic mutations may result, leading to
an increased resistance to the antibiotic that the microbes were exposed to at sub-cidal or
sub-inhibitory doses. Repeated or prolonged exposure to sub-therapeutic antibiotic
concentrations would further enrich the resistant strain. To investigate possible resistance,
the susceptibility to NO treatment following exposure to sub-inhibitory NO doses was
examined using the NO-releasing nitrosothiol-modified particles. Bacterial cultures were
treated with a range of concentrations both above and below the MIC for 24 h in nutrient
growth conditions employing a serial passage mutagenesis assay described previously.
[60,61] The assay was repeated by propagating the bacteria exposed to the highest
concentration of particles that did not inhibit growth. After the completion of 20 passages of
NO exposure in this manner, no sustained increases in the MIC for any of the bacterial
species were observed versus the parent strains (Table 2). The two-fold increase in
susceptibility observed for S. aureus and S. epidermidis was not significant and is
considered normal inter-experimental variation.
1.4 Conclusions
The inability of bacteria to develop resistance to exogenous NO delivered from a silica
vehicle was not surprising primarily because of the multiple mechanisms by which NO
presents toxicity towards microbes.[2,11,12,13,16,51] The hydrophobicity and small size of
NO allows it to rapidly migrate across bacterial lipid membranes where a number of
nitrosative and oxidative reactions may occur.[13] The diversity of NO's antimicrobial
mechanisms thus would require multiple mutations to occur simultaneously for microbial
survival, hindering resistance development. Nevertheless, it would be naïve to conclude that
bacteria absolutely cannot develop increased resistance to exogenous NO. Spellberg et al.
points out the fallacy of assuming that we (humans) can win a war against bacteria that have
been “creating and defeating antibiotics for 20 million times longer than Homo sapiens have
known that antibiotics existed.”[65] It is likely that the emergence of resistance to
exogenous NO will depend heavily on environmental conditions such as nutrient
availability, temperature, exposure duration/intensity, the presence of other bacterial species,
and infection location (i.e., in vivo vs. in vitro). Clearly, it is imperative that future studies
examining the efficacy of NO-releasing therapeutics also consider the ability of bacteria to
develop resistance, especially as such therapeutics are applied clinically.
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• We evaluate the ability of bacteria to develop a resistance to exogenous NO.
• Nitrosothiol nanoparticles were utilized as an exogenous antimicrobial model.
• Prolonged exposure to sub-therapeutic NO did not result in increased resistance.
• Single-dose exposure to bactericidal NO did not result in increased resistance.
• These assays may serve as a blueprint for future NO resistance studies.
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Representative NO release from 75 mol% MPTMS/TEOS particles in TSB at 37 °C. [Inset:
Enlarged view of NO release during 12–24 h.]
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Table 1
Minimum inhibitory concentrations of 75 mol% MPTMS/TEOS particles in TSB at 37 °C for 24 h (1010 cfu
mL-1 starting bacterial concentration) and spontaneous mutation parameters before and after exposure to
inhibitory concentrations of NO.
MIC24h (mg mL-1)
species ATCC# Day 1 Day 20 ΔMIC
S. aureus 29213 3.13 3.13 0
MRSA 33591 3.13 1.65 −50%
S. epidermidis 35983 6.25 3.13 −50%
E. coli (0157:H7) 35150 6.25 6.25 0
P. aeruginosa 19143 6.25 6.25 0
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